Investments
51Portfolio Exits
14Partners & Customers
10Service Providers
1About Bristol-Myers Squibb
Bristol-Myers Squibb (NYSE: BMY) is a global biopharmaceutical company committed to discovering, developing, and delivering medicines that help patients prevail over serious diseases.
Bristol-Myers Squibb Headquarter Location
430 E. 29th Street 14th Floor
New York, New York, 10016,
United States
800-332-2056
Expert Collections containing Bristol-Myers Squibb
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Bristol-Myers Squibb in 2 Expert Collections, including Digital Health.
Digital Health
419 items
Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)
Fortune 500 Investor list
590 items
This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.
Bristol-Myers Squibb Web Traffic
Bristol-Myers Squibb Rank
Research containing Bristol-Myers Squibb
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Bristol-Myers Squibb in 3 CB Insights research briefs, most recently on Apr 19, 2021.
Latest Bristol-Myers Squibb News
Jun 22, 2022
CVS Health will return blood thinner Eliquis to its pharmacy benefit manager's commercial formulary beginning July 1, reversing a decision that sparked protests from physicians and patients, the company notified providers last week. CVS Caremark negotiated a new arrangement with Eliquis maker Bristol-Myers Squibb to acquire the prescription anticoagulant. Both Eliquis and Janssen Pharmaceutical's Xarelto will be available to patients the PBM covers. For months, CVS Caremark's formulary included only Xarelto, even though research hasn't shown the two medications to be interchangeable. Patients, medical societies and advocacy groups such as the American College of Cardiology and American Society of Hematology objected when CVS Caremark disclosed last year that Eliquis would leave its formularly. A coalition called the Partnership to Advance Cardiovascular Health described the formulary exclusion as "dangerously disruptive" in a December letter to Dr. Troyen Brennan, then the company's chief medical officer. CVS Caremark decided to return Eliquis to its formulary after negotiating a lower net cost, a spokesperson wrote in an email Tuesday. "Anticoagulant therapies are among the non-specialty products where we are seeing the fastest cost increases from drug manufacturers and we will continue to push back on unwarranted price increases," the spokesperson wrote. The price of Eliquis, also known as apixaban, rose 6% to $529 for a one-month supply in January compared to a year before, according to Patients for Affordable Drugs, an advocacy organization. The cost of Xarelto, also known as rivaroxaban, increased 4.9% during the same period to $516 monthly, the report says. Because pharmacy benefit managers receive rebates from manufacturers for formulary placement, it is unknown how much CVS Caremark pays for these drugs. In addition to returning to CVS Caremark's commercial formulary, Eliquis will receive preferred treatment by CVS Health's Zinc group purchasing organization beginning July 1, a Bristol-Myers Squibb spokesperson wrote in an email. Group purchasing organizations serve as a rebate aggregators for other PBMs. In the months after CVS Caremark announced it would remove Eliquis from its formulary, Bristol-Myers Squibb launched a copay card that allowed some commercially insured patients, including those covered through CVS Caremark, to purchase the medicine for $10 a month. But because these drugs are so widely prescribed, not every physician was aware of this option, so access remained limited, said Dr. Geoffrey Barnes, a cardiologist and a professor at the University of Michigan. Barnes, a consultant to both Bristol-Myers Squibb and Johnson & Johnson-owned Janssen Pharmaceutcal, has discussed the impact of CVS Caremark's formulary exclusion with CVS Health executives, he said. "There is a larger conversation about the cost of medications in general, and how we keep those under control so that they're accessible to all patients," Barnes said. "That's something that's not just controlled by insurers or PBMs, but also by manufacturers. This is a complex problem." Pharmacy benefit managers typically do not reverse formulary decisions or modify coverage options mid-year, said Antonio Ciaccia, CEO of drug pricing research firm 46brooklyn Research and president of 3 Axis Advisors consultancy. "It shows you that an activated, pissed off and loud group of patients can impact PBM decisions that work against their wellbeing," he said. Patient and advocate Beth Joyner Waldron of Chapel Hill, North Carolina, has been a vocal critic of CVS Caremark's formulary change. Although her employer restored Eliquis to its drug list in February, Joyner Waldron, 52, sustained public pressure on CVS Health and its executives on social media, and credits patient activism with the company's shift. "This was an example of collective action," she said. The formulary change will take effect one month after the Federal Trade Commission announced an investigation of pharmacy benefit manager business practices Regulators will require CVS Caremark and the five other largest PBMs to reveal information about their operations to guage how their activities influence drug pricing and access. CVS Caremark, Cigna's Express Scripts and UnitedHealth Group's OptumRx collectively control about 80% of the PBM market, according to the FTC. Letter
Bristol-Myers Squibb Investments
51 Investments
Bristol-Myers Squibb has made 51 investments. Their latest investment was in Owkin as part of their Corporate Minority on June 6, 2022.
Bristol-Myers Squibb Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
6/8/2022 | Corporate Minority | Owkin | $80M | Yes | 4 | |
5/31/2022 | Series B | Sapience Therapeutics | $41M | No | 1 | |
5/11/2022 | Series A | Nuvig Therapeutics | $47M | Yes | 3 | |
4/21/2022 | Series B | |||||
4/14/2022 | Series B |
Date | 6/8/2022 | 5/31/2022 | 5/11/2022 | 4/21/2022 | 4/14/2022 |
---|---|---|---|---|---|
Round | Corporate Minority | Series B | Series A | Series B | Series B |
Company | Owkin | Sapience Therapeutics | Nuvig Therapeutics | ||
Amount | $80M | $41M | $47M | ||
New? | Yes | No | Yes | ||
Co-Investors | |||||
Sources | 4 | 1 | 3 |
Bristol-Myers Squibb Portfolio Exits
14 Portfolio Exits
Bristol-Myers Squibb has 14 portfolio exits. Their latest portfolio exit was Personal Genome Diagnostics on December 23, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
12/23/2021 | Acquired | 12 | |||
10/1/2021 | IPO | 3 | |||
3/26/2021 | IPO | 7 | |||
Date | 12/23/2021 | 10/1/2021 | 3/26/2021 | ||
---|---|---|---|---|---|
Exit | Acquired | IPO | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 12 | 3 | 7 |
Bristol-Myers Squibb Acquisitions
18 Acquisitions
Bristol-Myers Squibb acquired 18 companies. Their latest acquisition was Turning Point Therapeutics on June 03, 2022.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
6/3/2022 | Series D | $144.43M | Acq - Pending | 4 | ||
11/17/2020 | Series B | $94M | Acq - P2P | 8 | ||
8/24/2020 | Series C | $18.8M | Acquired | 10 | ||
11/21/2019 | ||||||
8/3/2017 | Other Venture Capital |
Date | 6/3/2022 | 11/17/2020 | 8/24/2020 | 11/21/2019 | 8/3/2017 |
---|---|---|---|---|---|
Investment Stage | Series D | Series B | Series C | Other Venture Capital | |
Companies | |||||
Valuation | |||||
Total Funding | $144.43M | $94M | $18.8M | ||
Note | Acq - Pending | Acq - P2P | Acquired | ||
Sources | 4 | 8 | 10 |
Bristol-Myers Squibb Partners & Customers
10 Partners and customers
Bristol-Myers Squibb has 10 strategic partners and customers. Bristol-Myers Squibb recently partnered with Immatics Biotechnologies on June 6, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
6/2/2022 | Partner | Germany | 1 | ||
6/2/2022 | Licensor | Germany | 7 | ||
5/12/2022 | Licensor | United States | In July 2021 , BridgeBio Pharma , Inc. initially announced a non-exclusive , co-funded clinical collaboration with Bristol Myers Squibb to evaluate the combination of BBP-398 with OPDIVO ® in patients with advanced solid tumors with KRAS mutations . | 1 | |
5/4/2022 | Partner | ||||
5/4/2022 | Licensor |
Date | 6/2/2022 | 6/2/2022 | 5/12/2022 | 5/4/2022 | 5/4/2022 |
---|---|---|---|---|---|
Type | Partner | Licensor | Licensor | Partner | Licensor |
Business Partner | |||||
Country | Germany | Germany | United States | ||
News Snippet | In July 2021 , BridgeBio Pharma , Inc. initially announced a non-exclusive , co-funded clinical collaboration with Bristol Myers Squibb to evaluate the combination of BBP-398 with OPDIVO ® in patients with advanced solid tumors with KRAS mutations . | ||||
Sources | 1 | 7 | 1 |
Bristol-Myers Squibb Service Providers
1 Service Provider
Bristol-Myers Squibb has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
---|---|---|---|
Acq - P2P | Investment Bank | Financial Advisor |
Service Provider | |
---|---|
Associated Rounds | Acq - P2P |
Provider Type | Investment Bank |
Service Type | Financial Advisor |
Partnership data by VentureSource
Bristol-Myers Squibb Team
157 Team Members
Bristol-Myers Squibb has 157 team members, including current Founder, President, Suresh Poosala.
Name | Work History | Title | Status |
---|---|---|---|
Suresh Poosala | National Institutes of Health, and St. Jude Children's Research Hospital | Founder, President | Current |
Lamberto Andreotti | Chief Executive Officer | Current | |
Giovanni Caforio | Chief Executive Officer | Current | |
Nadim Ahmed | President, Executive Vice President | Current | |
Teresa M Foy | Celgene, Oncofactor, VLST Corporation, and GSK | President, Senior Vice President | Current |
Name | Suresh Poosala | Lamberto Andreotti | Giovanni Caforio | Nadim Ahmed | Teresa M Foy |
---|---|---|---|---|---|
Work History | National Institutes of Health, and St. Jude Children's Research Hospital | Celgene, Oncofactor, VLST Corporation, and GSK | |||
Title | Founder, President | Chief Executive Officer | Chief Executive Officer | President, Executive Vice President | President, Senior Vice President |
Status | Current | Current | Current | Current | Current |
You May Also Like
DoubleRainbow Biosciences develops technologies rooted in the mechanistic understanding of specialized metabolic systems in plants and other organisms. The firm devises biosynthetic strategies that provide sustainable access to high-value natural products of medicinal or industrial significance.
Luminary Therapeutics is a biotechnology company based in Minneapolis, Minnesota.
GI Innovation is a bio-venture company that explores the development of new drugs through the combination of microbiome (human microorganism) and protein drugs.

Novartis (NYSE: NVS) is a global healthcare company that provides solutions to address the evolving needs of patients worldwide. Focusing solely on healthcare, Novartis offers a diversified portfolio to meet these needs including medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools, and consumer health products.

Kite Pharma is a clinical-stage biopharmaceutical company engaged in the development of cancer immunotherapy products, with a primary focus on eACT designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide range of cancer indications. Kite's management team has a proven track record of building successful biotechnology companies and successfully developing immunotherapies and other oncology treatments.

Johnson & Johnson (NYSE: JNJ) is a multi-national manufacturer of pharmaceutical, diagnostic, therapeutic, surgical, and biotechnology products, as well as personal hygiene products.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.